LifeStance Health CTO Sells 42,067 Shares for $541,402
Key Points
Vukasin Paunovich disposed of 42,067 shares.
The transaction involved shares equal to 17% of the total stake held by the executive prior to the filing.
The disposition consisted entirely of directly held shares.
Vukasin Paunovich, Chief Technology Officer of LifeStance Health Group (NASDAQ:LFST), sold 42,067 shares of common stock on Sept. 2, 2026, according to a recent SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Transaction value | $541,402 |
| Shares sold | 42,067 |
| Post-transaction shares (directly held) | 205,379 |
| Post-transaction value | $2.6 million |
Transaction value based on SEC Form 4 weighted average sale price ($12.87); post-transaction value based on Sept. 2, 2026, market close ($12.89).
Key questions
- How did this transaction affect the executive's total equity position?
Paunovich's direct equity holdings decreased to approximately 205,000 shares, representing a post-transaction market value of $2.6 million as of the Sept. 2, 2026, close. - What were the specific execution details for this sale?
The shares were sold at a weighted average price of $12.87, with individual transactions in the open market ranging from $12.86 to $12.905. - Where does the insider's ownership stand relative to the company's capital structure?
The remaining direct position held by the Chief Technology Officer accounts for approximately 0.05% of the company's total shares outstanding. - What is the primary operational focus of the company?
LifeStance Health Group specializes in outpatient mental healthcare services, offering psychiatric evaluations, neuropsychological testing, and various therapy modalities through a subsidiary network.
Company Overview
| Metric | Value |
|---|---|
| Share Price (as of market close 2026-09-04) | $12.73 |
| Market Capitalization | $4.8 billion |
| Revenue (TTM) | $1.6 billion |
| Net Income (TTM) | $50.6 million |
Company Snapshot
- LifeStance Health Group operates a comprehensive outpatient mental healthcare platform that delivers psychiatric evaluations, psychological and neuropsychological testing, and diverse therapeutic modalities, including individual, family, and group therapy sessions, across its subsidiary network.
- The company generates revenue through a diversified mental health services model that combines clinical care delivery with specialized diagnostic and therapeutic services, addressing a broad spectrum of mental health conditions for patients across multiple care settings.
- LifeStance serves patients seeking outpatient mental healthcare services, including individuals requiring psychiatric treatment, psychological assessment, and therapeutic intervention, positioning itself as a primary provider within the outpatient behavioral health market.
LifeStance Health Group operates as a scaled provider of outpatient mental healthcare services with a substantial footprint of 8,542 employees and $1.6 billion in TTM revenue. The company has demonstrated significant market momentum, with a one-year share price appreciation of 134.5%, reflecting investor confidence in the expanding demand for accessible mental health services. LifeStance's competitive positioning is anchored in its integrated subsidiary network model, which enables comprehensive service delivery across psychiatric care, specialized testing, and therapeutic interventions within the growing outpatient behavioral health sector.
What this transaction means for investors
On Sept. 2, Paunovich sold more than 42,000 shares in a transaction valued at over $541,000. While the number of shares may initially sound like a significant amount, a closer look at the transaction suggests it is largely a routine sale. While the insider sold 42,067 shares, Paunovich still holds 205,379 shares. That shows continued alignment with the company's success. In addition, there's also the stock price to consider. Over the past 12 months, LifeStance's shares have skyrocketed by 134.5%.
In comparison, the S&P 500 is up 16.6% over the same period. With the stock price climbing so high, it isn't out of the ordinary that an insider would consider selling some shares to take some gains off the table. Given the number of shares sold and retained and the stock price's significant outperformance of the S&P 500 over the last year, this sale, in and of itself, doesn't seem to indicate anything shareholders should be alarmed about.
Jack Delaney has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.